The World Market for Anti-infectives Volume II: The World Market for Antibacterial Medications

Attention: There is an updated edition available for this report.

Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20+ billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike speeding toward the market. The second volume of Kalorama’s ongoing market study on anti-infectives tackles this large and dynamic segment with a global report on the clinical, regulatory, business, and even political forces that are shaping the rapidly changing antibiotic market.

Don't forget to check out Volumes I and III of this exciting series! Purchase two volumes and save 10% or purchase the entire series and save 20%!

Volume I: The World Market for Antifungal Medications

Volume III: The World Market for Antiviral Medications

The World Market for Anti-infectives Series - Volumes I-III

Resistance Issues and Unmet Need Drive Antibiotic Market Toward $30 Billion

New York, January 21, 2003 /PR Newswire
— The worldwide market for antibacterial drugs will grow to almost $30 billion by 2006, according to a new study released today from Kalorama Information. Antibiotic-resistant strains of bacteria are challenging the industry to develop new drugs and creating sizable market potential for both large and small companies, according to the report.

World infection rates are on the rise on account of the AIDS pandemic and the effects of urbanization, globalization, and demographic shifts. In addition, troublesome antibiotic resistance is making many of the first-line treatments obsolete, adding to enormous unmet need for new, more potent drugs.

"Part of the problem is that there have been almost no truly new types of antibiotics commercialized in recent history," notes Steven Heffner, Acquisitions Editor at Kalorama Information. "Rather, ‘new’ antibiotics have mainly been modifications of the same class of compounds. And even Zyvox, the first truly new antibiotic class [oxazolidinones] to be developed in more than 30 years, induced detectable bacterial resistance within two years of its commercial release."

Antibiotic resistance and several impending big-name patent expirations are creating an increasingly competitive development environment, according to the report. Big pharma companies, small biotech concerns, and even many research institutions are in the hunt for new weapons to fight troublesome bacterial infections, with several notable successes on the horizon.

The study, The Worldwide Market for Antibacterial Drugs, represents the second volume of an ongoing study of anti-infective drug markets by Kalorama. The study discusses market size, market share, epidemiology of major infections, patent expirations, and pipeline products, as well as clinical and business trends affecting the industry. The first volume covered antifungal drugs, and the third volume, due out in March, will cover antiviral medications.

About Kalorama Information
Kalorama Information, an imprint of, supplies the latest in independent market research for the life sciences. For more information, contact Steven Heffner at 212-807-2634 or, or visit

About is the leading provider of global market intelligence products and services. With over 50,000 research publications from 350 research publishers, we offer instant online access to the world’s most extensive database of expert insights on global industries. Updated daily. For more information, contact Alison Williams at 301-468-3650 x203 or, or visit

Chapter One: Executive Summary

    Perspective on Anti Infective Pharmaceuticals

    Antibiotic Medications Overview

    • Current Drugs
    • The Need for New Drugs

    Market Orientation in Brief

    • Top Classes of Antibiotics
    • Top Classes of Antibiotics
    • Major Market Drugs
    • Major Market Players
    • Pipeline Therapies

    Issues Driving the Market

    • Antibiotic Resistance
    • Unnecessary Prescriptions
    • Patents

    Forecast Summary

    Scope and Methodology

Chapter Two: Introduction

    Microbiology of Infection
    • Gram Negative Bacteria
    • Gram Positive Bacteria

    Types of Compounds

    • Beta-lactamase
    • Clauvanic Acid
    • Imipenem
    • Sulbactam
    • Tazobactam
    • Cephalosporins
    • Macrolides
    • Sulfanilamide
    • Penicillin
    • Aminoglycosides
    • Chloramphenicol
    • Tetracyclines
    • Chlortetracycline
    • Quinolones
    • Fluoroquinolones

    Drug Use Patterns

    Resistance Issues

    • Trends
    • Macrolide Resistance
    • Streptococcus pneumoniae
    • Global Resistance Initiative
    • Natural Products

Chapter Three: Emerging Therapies

    Research Activities
    • Nasal Antibiotic
    • Iron Absorbing Mechanisms
    • Bacteriophages
    • Peptide Antibiotics
    • Targeting Enzymes
    • Blocking Pathways

    In the Pipeline

    Drug and Patent Exclusivity

Chapter Four: The World Market For Antibiotics


    Markets by Geographic Region

    • United States
    • Europe
    • Japan-Asia, Latin America, Africa

    Market Share by Type of Drug

    Major Market Drugs and Players

    Generic Competition

    • Generic Antibiotics Market
    • Generic Product Trends

    Pediatric Antibiotic Market

    • Otitis Media
    • Acute Epiglottitis
    • Meningitis
    • Urinary Tract Infections
    • Pediatric Market Forecast

    Market Issues

    • Emerging Disease Market Opportunity
    • Bioterrorism

Chapter Five: Company Profiles

  • Abbott Laboratories
  • ActivBiotics
  • Agis Industries Ltd.
  • AntexPharma Inc.
  • Aventis Pharma AG
  • AstraZeneca PLC
  • Bayer AG
  • Biochemie GmbH
  • Bristol-Myers Squibb Co.
  • British Biotech plc
  • CollaGenex Pharmaceuticals Inc.
  • Corus Pharma Inc.
  • Cubist Pharmaceuticals Inc.
  • Daiichi Pharmaceutical Co. Ltd.
  • DepoMed Inc.
  • Ecopia BioSciences Inc.
  • Eli Lilly and Co.
  • Elite Pharma Pvt. Ltd.
  • Elitra Pharmaceuticals
  • Enanta Pharmaceuticals Inc.
  • Essential Therapeutics Inc.
  • First Horizon Pharmaceutical Corp.
  • Fujisawa Pharmaceutical Co. Ltd.
  • Genome Therapeutics Corp.
  • GlaxoSmithKline plc
  • Hoffmann La Roche Ltd.
  • Ibis Therapeutics
  • Intrabiotics Pharmaceuticals Inc.
  • Johnson and Johnson
  • Medicis Pharmaceutical Corp.
  • Merck and Co. Inc.
  • NAEJA Pharmaceutical Inc.
  • Norcarex Bio Corp.
  • PanTherix Ltd.
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Recordati SpA
  • Salix Pharmaceuticals
  • Surya Pharmaceutical Ltd.
  • Taisho Pharmaceutical Co. Ltd.
  • Tanabe Seiyaku Ltd.
  • Toyama Chemical Co., Ltd.
  • Versicor Inc.

List of Exhibits

Chapter One

  • Figure 1-1: World Anti-Infective Drug Market Share by Type and Distribution Channel
  • Figure 1-2: Market Share for the Top Three Classes of Antibiotics
  • Table 1-1: Revenues of Top-Selling Prescription Antibiotic Drugs
  • Table 1-2: World Prescription Antibiotic Drug Market, Percentage Shares of Top Competitors

Chapter Two

  • Figure 2-1: Prescription Drug Use in the United States
  • Table 2-1: US Incidence Data for Selected Bacterial Disease
  • Table 2-2: Selected Resistent Infection Statistics
  • Table 2-3: Mortality Statistics for Major Infectious Diseases
  • Table 2-4: Epidemiologic Statistics for Most Common Infections

Chapter Three

  • Table 3-1: Notable Antibiotic Therapies in the Development Pipeline
  • Table 3-2: Exclusivity Expirations for Key Antibiotic Pharmaceuticals
  • Table 3-3: Patent Expirations for Key Antibiotic Pharmaceuticals

Chapter Four

  • Table 4-1: The World Market for Anti-Infective Medications, 2002-2006
  • Table 4-2: The World Market for Antibiotic Medications, 2002-2006
  • Table 4-3: The U.S. Market for Antibiotic Medications, 2002-2006
  • Table 4-4: The European Market for Antibiotic Medications, 2002-2006
  • Table 4-5: The Japanese-Asian Market for Antibiotic Medications, 2002-2006
  • Table 4-6: The Latin American Market for Antibiotic Medications, 2002-2006
  • Table 4-7: The African Market for Antibiotic Medications, 2002-2006
  • Figure 4-1: World Antibiotic Drug Market, Share by Type of Drug
  • Table 4-8: Revenues of Top-Selling Prescription Antibiotic Drugs
  • Figure 4-2: Market Share of Top-Selling Prescription Antibiotic Drugs
  • Table 4-9: Prescription Generic Anti-infective Drug ANDA Approvals, 2001
  • Table 4-10: The World Market for Antibiotic Medications Generic vs Branded Revenues, 2002-2006
  • Figure 4-3: Market Share of Generic vs Branded Antibiotic Medications 2002 and 2006
  • Table 4-11: Selected Prescription Antibiotics for Pediatric Administration
  • Table 4-12: The World Market for Antibiotic Medications Pediatric vs Non-Pediatric Revenues, 2002-2006
  • Table 4-13: Re-Emerging Infectious Disease, Selected Recent Cases

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook